114 related articles for article (PubMed ID: 15250064)
1. Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Ott SM
N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15250064
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Bjarnason NH
N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15247362
[No Abstract] [Full Text] [Related]
4. [Current osteoporosis treatment: reasons for adding vitamin D to alendronate].
Anić B; Grazio S
Reumatizam; 2006; 53(2):63-5. PubMed ID: 17580557
[TBL] [Abstract][Full Text] [Related]
5. [Long-term usefulness of alendronate confirmed. Bones still benefit even after 10 years].
MMW Fortschr Med; 2005 Jan; 147(1-2):53. PubMed ID: 15704575
[No Abstract] [Full Text] [Related]
6. Alendronate in postmenopausal osteoporosis.
McGrath H
N Engl J Med; 1996 Mar; 334(11):734; author reply 734-5. PubMed ID: 8594443
[No Abstract] [Full Text] [Related]
7. Do not use bisphosphonate therapy indefinitely for fracture prevention.
Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
[TBL] [Abstract][Full Text] [Related]
8. Alendronate: a new bisphosphonate for the treatment of osteoporosis.
Keen RW; Spector TD
Br J Clin Pract; 1996 Jun; 50(4):211-7. PubMed ID: 8759568
[TBL] [Abstract][Full Text] [Related]
9. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
10. Alendronate in the treatment of osteoporosis.
Adami S
Aging (Milano); 1998 Apr; 10(2):159-60. PubMed ID: 9666215
[No Abstract] [Full Text] [Related]
11. The treatment of postmenopausal osteoporosis.
Sambrook PN
N Engl J Med; 1995 Nov; 333(22):1495-6. PubMed ID: 7477151
[No Abstract] [Full Text] [Related]
12. Decimal point--osteoporosis therapy at the 10-year mark.
Strewler GJ
N Engl J Med; 2004 Mar; 350(12):1172-4. PubMed ID: 15028820
[No Abstract] [Full Text] [Related]
13. Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis.
Dempster DW
J Bone Miner Res; 1997 Aug; 12(8):1152-4. PubMed ID: 9258744
[No Abstract] [Full Text] [Related]
14. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Bize R; Lamy O; Peytremann-Bridevaux I
Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
[No Abstract] [Full Text] [Related]
15. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
16. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
17. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic prevention of osteoporotic fractures.
Zizic TM
Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
[TBL] [Abstract][Full Text] [Related]
19. [Alendronate once a week].
Brixen KT; Mosekilde L
Ugeskr Laeger; 2003 Jun; 165(27):2734-9. PubMed ID: 12886563
[No Abstract] [Full Text] [Related]
20. What's the story with Fosamax? Recent reports have women wondering if they should stop taking this widely prescribed osteoporosis drug.
Harv Womens Health Watch; 2008 Nov; 16(3):1-2. PubMed ID: 19043857
[No Abstract] [Full Text] [Related]
[Next] [New Search]
